Almirall, a CataloniaBio & HealthTech member, has been selected by the IBEX Technical Advisory Committee to join the IBEX 35, the benchmark stock market index of the Madrid stock exchange (Spain). 

The pharmaceutical company was founded in 1943. In 2017, Almirall refocused its strategy on medical dermatology.

Currently, Almirall has a direct presence in 21 countries through 13 subsidiaries, with more than 1,800 employees. The newest entrant to the IBEX 35 operates an three R&D centres in Sant Feliu de Llobregat (Barcelona), Reinbek (Germany) and Exton (USA); and three plants in Sant Andreu de la Barca (Barcelona), Sant Celoni (Barcelona) and Reinbek.

Almirall closed 2019 with total revenues of €908 million, achieving an EBITDA of €304 million.

More information

Photo: Headquarters of Almirall in Barcelona

You also may be interested in:

• Almirall acquires the American Bioniz Therapeutics
• Almirall starts Phase III trials of lebrikizumab for severe atopic dermatitis